N. Dhiantravan

Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will α Beat β?

M. Hofman, A. R. Ravi Kumar, N. Dhiantravan, 2021, European urology.

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy.

N. Lawrentschuk, D. Murphy, S. Keam, 2020, European urology focus.

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

M. Stockler, A. Scott, C. Gedye, 2021, The Lancet.

The role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer.

N. Lawrentschuk, D. Murphy, M. Hofman, 2021, Future oncology.

UpFrontPSMA: a randomized phase 2 study of sequential 177Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial protocol)

D. Murphy, I. Davis, M. Hofman, 2021, BJU international.

A role of PSMA PET/CT in multimodality imaging approach in adenoid cystic carcinoma

Lachlan McDowell, A. R. Ravi Kumar, K. Cavanagh, 2020, Journal of medical imaging and radiation oncology.

UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naïve prostate cancer (mHNPC).

D. Murphy, I. Davis, M. Hofman, 2021 .

Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study.

N. Lawrentschuk, P. Jackson, S. Sandhu, 2023, European urology.

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management

A. Pearce, J. Yaxley, A. Tariq, 2023, European Journal of Nuclear Medicine and Molecular Imaging.